Patients receiving insulin therapy exhibited the highest autoantibody burden (mean 1.56 ± 0.05), with T1DM patients showing significantly greater mean positivity (1.74 ± 0.05) compared to T2DM (0.53 ± 0.08; p < 0.0001). This evidence concerns the gene INS and type 1 diabetes mellitus.